Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Cara Therapeutics brings in $4.8mm from Series D round

Executive Summary

Cara Therapeutics Inc. (pain and inflammation) has raised $4.8mm of a potential $15mm through its Series D round. The company sold equity, preferred shares, and other rights to 12 investors including new buyer Rho Ventures (lead) and returning backers Alta Biopharma, Ascent Biomedical Ventures, CT Innovations, Devon Park BioVentures, Healthcare Private Equity, Mitsubishi, and MVM Life Science Partners. Proceeds will be used to continue development of Cara's lead candidate CR845, a peripherally restricted kappa opioid agonist in Phase II for post-operative pain.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies